AR077087A1 - Microparticulas de dicetopiperazina con contenidos de isomeros definidos - Google Patents
Microparticulas de dicetopiperazina con contenidos de isomeros definidosInfo
- Publication number
- AR077087A1 AR077087A1 ARP100102093A ARP100102093A AR077087A1 AR 077087 A1 AR077087 A1 AR 077087A1 AR P100102093 A ARP100102093 A AR P100102093A AR P100102093 A ARP100102093 A AR P100102093A AR 077087 A1 AR077087 A1 AR 077087A1
- Authority
- AR
- Argentina
- Prior art keywords
- microparticles
- fdkp
- dicetopiperazine
- isomers
- contents
- Prior art date
Links
- 239000011859 microparticle Substances 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 abstract 3
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- BBNKIRVUCQNAQR-FETIZUMASA-N (e)-4-[4-[(2s,5s)-5-[4-[[(e)-3-carboxyprop-2-enoyl]amino]butyl]-3,6-dioxopiperazin-2-yl]butylamino]-4-oxobut-2-enoic acid Chemical group OC(=O)\C=C\C(=O)NCCCC[C@@H]1NC(=O)[C@H](CCCCNC(=O)\C=C\C(O)=O)NC1=O BBNKIRVUCQNAQR-FETIZUMASA-N 0.000 abstract 1
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229940094417 fumaryl diketopiperazine Drugs 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000000199 parathyroid hormone Substances 0.000 abstract 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000012383 pulmonary drug delivery Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18677909P | 2009-06-12 | 2009-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077087A1 true AR077087A1 (es) | 2011-08-03 |
Family
ID=43306942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102093A AR077087A1 (es) | 2009-06-12 | 2010-06-14 | Microparticulas de dicetopiperazina con contenidos de isomeros definidos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8227409B2 (enExample) |
| EP (2) | EP3556356B1 (enExample) |
| JP (2) | JP5859432B2 (enExample) |
| KR (1) | KR101782174B1 (enExample) |
| CN (1) | CN102458371B (enExample) |
| AR (1) | AR077087A1 (enExample) |
| AU (1) | AU2010259939B2 (enExample) |
| BR (1) | BRPI1010722B1 (enExample) |
| CA (1) | CA2765156C (enExample) |
| ES (2) | ES2751107T3 (enExample) |
| IL (1) | IL216910A (enExample) |
| MX (1) | MX2011013313A (enExample) |
| MY (1) | MY172858A (enExample) |
| RU (1) | RU2490026C1 (enExample) |
| SG (4) | SG176778A1 (enExample) |
| TW (1) | TWI513692B (enExample) |
| WO (1) | WO2010144785A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| EP1494732B1 (en) | 2002-03-20 | 2008-01-30 | MannKind Corporation | Inhalation apparatus |
| US20070027063A1 (en) * | 2004-01-12 | 2007-02-01 | Mannkind Corporation | Method of preserving the function of insulin-producing cells |
| DK1786784T3 (da) | 2004-08-20 | 2011-02-14 | Mannkind Corp | Katalyse af diketopiperazinsyntese |
| CN104436170B (zh) | 2004-08-23 | 2018-02-23 | 曼金德公司 | 用于药物输送的二酮哌嗪盐 |
| AU2006290227B2 (en) | 2005-09-14 | 2012-08-02 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| KR20080096809A (ko) | 2006-02-22 | 2008-11-03 | 맨카인드 코포레이션 | 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법 |
| ES2302448B1 (es) * | 2006-10-20 | 2009-05-08 | Vodafone España, S.A. | Sistema y metodo de difusion de informacion de area en entornos locales de tamaño reducido dentro de un sistema celular de comunicaciones moviles. |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| SG10201507036TA (en) | 2008-06-13 | 2015-10-29 | Mannkind Corp | A dry powder inhaler and system for drug delivery |
| EP2609954B1 (en) | 2008-06-20 | 2021-12-29 | MannKind Corporation | An interactive apparatus for real-time profiling of inhalation efforts |
| TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| MX2011009512A (es) | 2009-03-11 | 2011-11-29 | Mannkind Corp | Aparato, sistema y metodo para medir la resistencia de un inhalador. |
| MY157166A (en) | 2009-06-12 | 2016-05-13 | Mankind Corp | Diketopiperazine microparticles with defined specific surface areas |
| CA2778698A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
| IL223742A (en) | 2010-06-21 | 2016-06-30 | Mannkind Corp | A dry powder inhaler and preparation for it |
| CN103108650A (zh) | 2010-08-25 | 2013-05-15 | Atyr医药公司 | 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| EP2694402B1 (en) | 2011-04-01 | 2017-03-22 | MannKind Corporation | Blister package for pharmaceutical cartridges |
| ES2572915T3 (es) | 2011-06-02 | 2016-06-03 | The University Of Louisville Research Foundation, Inc. | Nanopartículas conjugadas a un agente antinucleolina |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| HK1200318A1 (en) | 2011-10-24 | 2015-08-07 | 曼金德公司 | Methods and compositions for treating pain |
| EP2872205B1 (en) | 2012-07-12 | 2017-02-08 | MannKind Corporation | Dry powder drug delivery systems |
| US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
| WO2014144895A1 (en) * | 2013-03-15 | 2014-09-18 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
| KR102465025B1 (ko) | 2013-07-18 | 2022-11-09 | 맨카인드 코포레이션 | 열-안정성 건조 분말 약제학적 조성물 및 방법 |
| EP3030294B1 (en) | 2013-08-05 | 2020-10-07 | MannKind Corporation | Insufflation apparatus |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| US9968125B2 (en) | 2015-01-09 | 2018-05-15 | Philip Morris Products S.A. | Nicotine—diketopiperazine microparticle formulations and methods of making the same |
| PT108368B (pt) * | 2015-03-31 | 2018-11-05 | Hovione Farm S A | Produção contínua de partículas |
| AU2017211410B2 (en) * | 2016-01-29 | 2022-10-13 | Mannkind Corporation | Dry powder inhaler |
| WO2021202425A1 (en) | 2020-03-28 | 2021-10-07 | University Of Louisville Research Foundation, Inc. | Methods of inhibiting or treating coronavirus infection, and methods for delivering an anti-nucleolin agent |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT83613B (en) | 1985-10-28 | 1988-11-21 | Lilly Co Eli | Process for the selective chemical removal of a protein amino-terminal residue |
| US6331318B1 (en) * | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5693338A (en) * | 1994-09-29 | 1997-12-02 | Emisphere Technologies, Inc. | Diketopiperazine-based delivery systems |
| US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| US5888477A (en) * | 1993-01-29 | 1999-03-30 | Aradigm Corporation | Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin |
| US5506203C1 (en) * | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
| US5547929A (en) * | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| ATE270097T1 (de) | 1998-04-09 | 2004-07-15 | Celanese Ventures Gmbh | Partikulärer wirkstoffträger für die pulmonale applikation |
| US9006175B2 (en) * | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| EP2280004B1 (en) * | 1999-06-29 | 2016-04-20 | MannKind Corporation | Pharmaceutical formulations comprising insulin complexed with a diketopiperazine |
| US7464706B2 (en) | 1999-07-23 | 2008-12-16 | Mannkind Corporation | Unit dose cartridge and dry powder inhaler |
| EP1494732B1 (en) * | 2002-03-20 | 2008-01-30 | MannKind Corporation | Inhalation apparatus |
| US7625865B2 (en) * | 2004-03-26 | 2009-12-01 | Universita Degli Studi Di Parma | Insulin highly respirable microparticles |
| DK1786784T3 (da) | 2004-08-20 | 2011-02-14 | Mannkind Corp | Katalyse af diketopiperazinsyntese |
| CN104436170B (zh) | 2004-08-23 | 2018-02-23 | 曼金德公司 | 用于药物输送的二酮哌嗪盐 |
| CA2592776A1 (en) * | 2005-01-10 | 2006-08-17 | Mannkind Corporation | Methods and compositions for minimizing accrual of inhalable insulin in the lungs |
| AU2006290227B2 (en) | 2005-09-14 | 2012-08-02 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| KR20080096809A (ko) * | 2006-02-22 | 2008-11-03 | 맨카인드 코포레이션 | 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법 |
| WO2007121411A2 (en) | 2006-04-14 | 2007-10-25 | Mannkind Corporation | Glucagon-like peptide 1(glp-1) pharmaceutical formulations |
| KR101736502B1 (ko) * | 2007-10-24 | 2017-05-16 | 맨카인드 코포레이션 | Ｇｌｐ-1에 의한 유해 효과의 예방 방법 |
| KR20100090692A (ko) * | 2007-10-24 | 2010-08-16 | 맨카인드 코포레이션 | 활성제의 전달 |
| SG10201507036TA (en) * | 2008-06-13 | 2015-10-29 | Mannkind Corp | A dry powder inhaler and system for drug delivery |
-
2010
- 2010-06-11 MY MYPI2011006016A patent/MY172858A/en unknown
- 2010-06-11 ES ES10724973T patent/ES2751107T3/es active Active
- 2010-06-11 RU RU2012100785/15A patent/RU2490026C1/ru active
- 2010-06-11 JP JP2012515175A patent/JP5859432B2/ja active Active
- 2010-06-11 MX MX2011013313A patent/MX2011013313A/es active IP Right Grant
- 2010-06-11 EP EP19175215.3A patent/EP3556356B1/en active Active
- 2010-06-11 US US12/813,839 patent/US8227409B2/en active Active
- 2010-06-11 SG SG2011091410A patent/SG176778A1/en unknown
- 2010-06-11 TW TW099119045A patent/TWI513692B/zh active
- 2010-06-11 CN CN201080026117.7A patent/CN102458371B/zh active Active
- 2010-06-11 SG SG2013076096A patent/SG195546A1/en unknown
- 2010-06-11 BR BRPI1010722 patent/BRPI1010722B1/pt active IP Right Grant
- 2010-06-11 WO PCT/US2010/038287 patent/WO2010144785A2/en not_active Ceased
- 2010-06-11 SG SG10201706995VA patent/SG10201706995VA/en unknown
- 2010-06-11 EP EP10724973.2A patent/EP2440186B1/en active Active
- 2010-06-11 AU AU2010259939A patent/AU2010259939B2/en active Active
- 2010-06-11 ES ES19175215T patent/ES2880102T3/es active Active
- 2010-06-11 SG SG10201403147SA patent/SG10201403147SA/en unknown
- 2010-06-11 KR KR1020127000804A patent/KR101782174B1/ko active Active
- 2010-06-11 CA CA2765156A patent/CA2765156C/en active Active
- 2010-06-14 AR ARP100102093A patent/AR077087A1/es not_active Application Discontinuation
-
2011
- 2011-12-12 IL IL216910A patent/IL216910A/en active IP Right Grant
-
2015
- 2015-09-07 JP JP2015176164A patent/JP6101326B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY172858A (en) | Diketopiperazine microparticles with defined isomer contents | |
| EA201792345A1 (ru) | Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями | |
| PE20130511A1 (es) | Formulaciones de insulina de accion prolongada | |
| CL2012002031A1 (es) | Composición farmacéutica que contiene al menos un compuesto fgf-21 (factor de crecimiento de fibroblastos 21) y al menos un agonista del glp-1r (receptor del péptido 1 similar al glucagón); y su uso para preparara un medicamento para el tratamiento de al menos un síndrome metabólico y/o aterosclerosis en un paciente. | |
| AR117001A2 (es) | Formulación de premezcla de dexmedetomidina | |
| CL2018000299A1 (es) | Composiciones con potenciadores de impregnacion para el suministro de fármacos. | |
| AR092862A1 (es) | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion | |
| AR077086A1 (es) | Microparticulas de dicetopiperazina con superficies especificas definidas | |
| CL2013003547A1 (es) | Peptido derivado de oxintomodulina; polinucleotido que lo codifica; composicion farmaceutica que lo comprende; uso del peptido para tratar la obesidad. | |
| MX2016001971A (es) | Composiciones farmaceuticas parenterales acuosas estables de peptidos insulinotropicos. | |
| PE20150762A1 (es) | Formulaciones de etanercept que muestran una marcada reduccion de la cantidad de particulas subvisibles | |
| SG10201806300VA (en) | Liquid pharmaceutical composition | |
| AR079890A1 (es) | Estabilizacion de peliculas de oxido de zinc en composiciones bucales | |
| CU24504B1 (es) | Unidad de dosificación orodispersable que contiene un componente estetrol y un proceso que incluye un paso de granulación para preparar el mismo | |
| EA201190127A1 (ru) | Фармацевтические составы нитазоксанида с контролируемым высвобождением | |
| PE20140724A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
| MX359413B (es) | Metodos de tratamiento de carcinoma hepatocelular. | |
| PH12018500690A1 (en) | Novel insulin analogs and use thereof | |
| MX2017007699A (es) | Formulacion de proporcion fija de insulina glargina/lixisenatida. | |
| MY175781A (en) | Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation | |
| JP2012530062A5 (enExample) | ||
| CL2010000063A1 (es) | Nanoparticulas de policosanol que comprenden 70% a 90% de octacosanol y una fraccion estabilizadora de succinato de tocoferilpolietilenglicol (1000) (tpgs); composicion farmaceutica; forma de dosis unitaria; y uso para tratar resistencia a la insulina y diabetes. | |
| ECSP19044591A (es) | Amidas aromáticas de ácido carboxílico como antagonistas del receptor b1 de la bradiquinina | |
| MY191712A (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
| CO6630127A2 (es) | Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FC | Refusal |